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kg/day by intravenous infusion over I hour. Serum gentamicin concentra-
tions (SGC) were measured by fluorescence polarization immunoassay at 10
minutes, 2 hours and 9 hours after completion of the first gentamicin
infusion. The IBWI, creatinine clearance (CrCI), and gentamicin elimina-
tion rate (Ke), volume of distribution (Vd), and clearance (Cl) were
determined for each subject according to standard formulas. The 2 groups
were compared for the range of Vd, Ke and Cl, and the % of children
attaining desired peak serum gentamicin levels (pGl).
Results: Thirty three children in group 1 and 26 children in group 2 were
studied. There was no difference in age, weight, height, gender, body surface
area, mw, serum creatinine, and CrCI, between the 2 groups. The
gentamicin pharmacokinetic parameters for group I were: Cl 0.12 ±
0.09 l/hr/kg; Vd0.45 ± 0.39 lfkg; and Ke 0.33 ± 0.1 hr-1. For group 2, the
parameters were as follows: CL 0.12 ± 0.06 L/hr/kg; Vd 0.45 ± 0.31 L/kg;
and Ke 0.31 ± 0.1 hr-1. These differences were not statistically significant.
The % of children attaining PGL's were 67% and 52% for groups 1 & 2
respectively.
conduslon: In this study, there was no difference in the pharmacokinetics of
gentamicin single daily dosing between children with and without leukemia.
IMoP255I The use and therapeutic drug monitoring (TOM) of
telcoplanln In the UK
E. S. R. Darley, A. P. MacGowan, 1. O. White
BCARE, Southmead Hospital, Bristol, United Kingdom
Objective: To assess current use, dosage and TOM ofteicoplanin (T) in UK.
Method: Questionnaires were sent to the 241 Microbiology laboratories
participating in UK NEQAS for antibiotic assays. Information was collected
on the choice ofglycopeptide, reasons for preference, dosing and TOM ofT,
and guidance used to achieve therapeutic dosing.
Results: 149 responses were received. 139/149 (93%) centres used T, 55
(40%) as their first choice glycopeptide. The commonest reason for this was
'no need for assays'. 79 (57%) centres used Vancomycin (V) as first choice,
the commonest reason being 'cost'. Doses recommended, frequency of use
of TDM and desired pre-dose concentrations for staphylococcal soft-tissue
infection and bacteraemia were all lower in the group which used T in
preference to V. 9/21 (43%) responses from this group stated a pre-dose
concentration should be > 20 mg/L for MRSA bacteraemia compared to
20/35 (57%) ofthose who preferred V. Of the 55 centres favouring T, 52%
rely mainly on datasheet recommendations and 11 % on assay results in
determining T doses. (n = 55). In comparison, the findings were 29% and
26% respectively from centres using V as first choice glycopeptide (n = 79).
Condusion: The majority of hospitals sampled use T. however V is the
glycopeptide of choice in 57% of these. Those preferentially using T
recommend lower doses, seek lower pre-dose concentrations and perform
less TDM when using T than those which prefer V.
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IMoP256I Antimicrobial activity of selected non antibiotic
drugs
S. Tyski, H. Kruszewska, T. Zar~ba
Department ofAntibiotics and Microbiology, Drug Institute, Warsaw, Poland
Some drugs which do not belong to the group ofantibiotics, ego cytostatics,
anaesthetics or vasodilators may also show the antimicrobial activity. The
aim of the study was to detect and characterise the antimicrobial activity
expressed by selected non antibiotic drugs analysed during state control
performed in Drug Institute. Over 60 drugs were randomly chosen from
different groups. The surveillance study was performed on standard micro-
bial strains: S. aureus ATCC 6538 P, E. coli ATCC 8739, P. aeruginosa ATCC
15442 and C. albicans ATCC 10231. The blotting-paper discs soaked with
solutions of drugs in concentration 0.1 g or 0.1 mill ml phosphate buffer
after drying were placed onto surface of the agar medium with smeared
suitable strain. Size ofgrowth inhibition zone corresponded to antimicrobial
activity ofdrug. It was found that the following drugs inhibited growth ofat
least one ofthe examined strains: Platidiam (SO mg-amp.) Platamine (SO mg-
amp.), Sinemet (125 mg-tab!.), Sensit (50 mg-drag.), Seractil (400 mg-tab!.),
Acesan (75 mg-tabl.), Zyban (150 mg-tab!.), Sermion (4 mg-amp.), Metho-
trexat "Ebewe" (50 mg-amp.) , Naproxen (500 mg-tab!.),Benuron (500 mg-
tab!.), Tarproxen (500 mg-tab!.), Septofervex (2 mg-tab!.) and Nospa Forte
(60 mg-tab!.). It was interesting, that strong antimicrobial activity of
methotrexate was limited to Staphyloco"us aureus strain. Minimal inhibitory
concentration of methotrexate was determined by agar dilution method
with the use of 56 clinical S. aureus strains (MRSA-32. MSSA-24). For
MSSA strains, MIC50-1O J.lg/ml, MIC90-15 J.lg/m1 (range: 10-20 ",g/m1).
For MRSA strains, MICS0-20 ",g/ml, MIC90-SO ",g/ml (range: 10- > 100
J.lg/ml).
IMoP257I Comparison of ecological effects on the
oropharyngeal microflora after treatment of acute otitis media
with suspensions of cefuroxime axetil or co-amoxyclawlanate
in children
B. Lund!, C. Edlundl , B. Rynnel-Dagool , Y. Lundgren2,J. Sterner3 , C.
E. Nord l
'Huddinge University Hospital, Karolinska Institutet; 2Dalens Sjukhus; Jparsta
Medical Consulting, Stockholm, Sweden
ObjectIves: To compare the effects on the oropharyngeal microflora in
children with AOM (acute otits media) treated with either cefuroxime
axetil, administered as an inactive prodrug, or eo-amoxyclavulanate, admi-
nistered in active form, and to evaluate the efficiency ofthese two antibiotics.
Methods: In this prospective trial 19 patients, 0.5-5 years old, diagnosed
with AOM were enrolled. The children were randomised to receive either
cefuroxime axetil15 mg/kg twice daily or co-amoxyclavu1anate 13.3 mg/kg
three times daily for seven days. Nasopharygeal and saliva samples were
collected before, immediately after, and two weeks after treatment. The
saliva samples were quantitatively and qualitatively analysed with respect to
microbial content. Nasopharyngeal samples were qualitatively analysed. All
isolates were tested for /3-lactamase production.
Results: No marked difference between the groups regarding the normal
flora or colonisation of pathogens was observed. In the cefuroxime axetil-
group 85% of the subjects were infected with Streptococcus pneumoniat',
H.mophilus influenza. or Moraxella cata"halis on day 0, the corresponding
figure for day 7 and 21 was 55%. In the co-amoxyclavulanate-group the
infection rate were 85% on day 0, 40% on day 7 and 85% on day 21
respectively. The main {1-lactamase producer was M. cata"halis.
conduslons: The local high concentration of antibiotics in oropharynx
right after intake ofantibiotic suspensions seems to have little or none impact
on the microbial flora in this region, and the antibiotic conccntraion in saliva
via systemic distribution seems high enough. for both compounds, to give
rise to a disturbed oropharyngeal microbial flora. Children seems prone to
either reinfection or persistance of pathogens within two weeks after
treatment.
IMoP25SIlack of dysautonomia with use of Iinezolid and
MAO-interacting meds
c. S. Hartman, T. S. Leach, V. Le, W. M. Todd, B. Hafkin
Pharmacia and Upjohn, KalaltUJZoo, MI, United States
Objectives: Linezolid, the first oxazolidinone to complete phase III testing,
has broad activity against susceptible and resistant Gram-positive infections.
Based on preclinical and phase I data, LZD is a weak, reversible monoamine
oxidase (MAO) inhibitor. We present vital sign data on phase III patients
who had received both LZD and an MAO-interacting medication.
Methods: Vital signs from baseline (BL), day 3 (03) and end of therapy
(EOT) were compared within and between treatment groups for all
hospitalized, phase III study subjects who had received at least 24 hours of
an MAO-interacting med before the first dose ofstudy drug. P-values were
calculated within groups using a paired t-test and between groups using one-
wayANOVA.
Results: For those patients with vitals at BL, D3 and/or EOT, 226 LZD
subjects received an MAO-int. med versus 203 in the comparator arm. Use
ofinteracting meds by class were roughly proportional between groups and
included sympathomimetics, vasopressors, SSRIs and miscellaneous anti-
depressants, select analgesics, and others. Baseline temperature (Centigrade),
blood pressure (mmHg) and pulse (per minute) for the LZD and comparator
subjects were 37.5, 129/69,96, and 37.6, 127/69,95, respectively. By D3,
vitals in the LZD group were 37.0, 130/72,87 versus 37.1, 130/70,89 for
comparator (all p values> 0.21). By EOT, vitals were 36.8,129/72,89 in
lZD subjects versus 36.9, 125/71,87 for comparator (all p values> 0040).
Consistent with resolution of infection, body temperature and pulse were
significandy lower at D3 and EOT within both groups (p < 0.0002) when
compared to baseline.
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Conclusion: Patients who received LZD in combination with an MAO-int.
med had similar vital signs at D3 and EOT relative to comparator suggesting
a lack of clinically significant MAO inhibition by LZD.
IMoP2S9 I Pharmacology of quinupristinldalfoprlstin and
other antl-bacterial agents against MSSA
E. Pfeil!, I. Gustafsson2, E. Uiwdin2, O. Cars2, B. Wiedemannl
'Pharm. Microbiology, University ofBonn, Bonn, German y; lDep. ofdin.
Microbiology, University Hospital, Uppsala, Sweden
Objectives: The aim of this study w.s to compare the pharmacodynamic
properties of quinupristin/dalfopristin (Q/D) with those of vancomycin
(VAN), moxifloxacin (MOX), roxithromycin (ROX), and ccftriaxonc
(CRO) against one Staphylococcus aureus strain (MSSA) using different
concentration-time-profiles (CTP) of the drugs.
Methods: We used an open and a closed pharmacological in-vitro model to
simuIatethcCTl'ofa) acontinousinfusion (Cl) (C = 10 x MIC), b) anoncc
daily dose (OD) or c) a twice daily dose (TD) (Q/D). To evaluate the efficacy
of antibiotics three different parameters (kama.: maximal killing activity,
ka2b: killing activity within 2 h, AAC: area above killing curve) were
calculated.
Results
kam.. (log dif. cfu) ka2h (log di£ cfu I MC (log dif. cfu x hI
CTP CI OD TD CI OD m CI OD TD
Q/D -4.63 -5.25 -5.11 -3.65 -4.98 -4.61 98.25 45.43 110.2
MOX -4.22 -4.53 n.d -2.43 -3.74 n.d 87.84 96.45 n.d
VAN -3.28 -2.7 n.d -1.13 -0.55 n.d 61.32 49.11 n.d
CRO -2.77 -2.55 n.d -0.97 -1.59 n.d 60.23 52.75 n.d
ROX -2.51 -1.89 n.d -0.81 -1.4 n.d 45.00 20.78 n.d
Conclusion: Q/D (CI, TD) shows the highest efficacy of the tested anti-
biotics against MSSA. Only the efficacy of MOX (CI, OD) is comparable.
After a once daily dose the efficacy (measured as AAC) of Q/D is reduced,
because of its short half-time. Nevertheless it is as effective as VAN and
CRO and more effective as ROX.
IMoP260! Pharmacodynamic parameten of efficacy «(max
and T> MIC) for amoxicillin against pneumococci with reduced
penicillin susceptibility
I. Gustafsson, E. Ldwdin, I. Odenholt, O. Cars
Dept. of Inj. Diseases, University Hospital, Uppsala, Sweden
Objectives: To study the pharmacokinetic parameters for efficacy (Cmax
and time above MIC: T > MIC) for amoxicillin on three strains of S.
pneumoniae with different susceptibility to penicillin.
Methods: The bacteria were exposed to amoxicillin in an in vitro kinetic
model. The initial dose (Cmax) and the elimination rate were varied so that
the T > MIC ranged from 30 to 100% of 24 h while the area under the
serum concentration- vs.-time curve (AUC) was constant. The bacteria
were followed by viable counts.
Results: Penicillin susceptible strain (PSP) of S. pneumoniae (MIC = 0.03
mgfl) showed maximal killing with ~logl0 -4.3 cfu/ml when T > MIC
was 50% or more during the 24 h observation period. For a strain (pIP) with
intermediate MIC of 0.25 mg/l regrowth occurred even when T > MIC
excceded 50%. However when these experiments were repeated with a
higher Cmax (5 x MIC) maximal killing were obtained at 50% T > MIC.
A third pneumococci strain, PRP (MIC = 4 mg/l) showed a different
pattern were aIoglO varied from -I to -4.3 even with an initial concen-
tration of 10 or 20 times MIC and an elimination rate giving 100% T >
MIC.
Conclusions: For the PSP and PIP strains T > MIC correlated with
maximal killing. However for PIP Cmax of 5 x MIC was also necessary.
The PRP strain showcd variable killing pattern which did not correlate with
the pharmacodynamic parameters and could be depending on whether the
autolysis was triggered or not,
IMoP261I Pharmacokinetics and comparative effects of
tellthromycin (HMR 3647) and darlthromycin on the oral and
intestinal microflora
C. Edlundl .:!, G. Alv:in l , l. Barkholtl , F. Vacheron3, P. Nabet3, C. E.
Nord l
tHuddinge University Hospital, Karolinska Institute; 2Siidertijrns hiigskola,
University College, Stockholm, Sweden; 3Aventis, Romainville, France
Objectives: To study the pharmacokinetics in plasma and saliva in healthy
volunteers and the effect on the normal oropharyngeal and intestinal
microflora of telithromycin (TEL), a new ketolide which is designed for
therapy ofcommunity acquired respiratory tract infections, and compare it
with that ofdarithromycin (CLA).
Methods: Ten subjects received 800 mg TEL perorally once daily and ten
other subjects received 250 mg ClA BID for 10 days. Blood, saliva and
faecal specimens were collected at defined intervals before, during ~nd a~ter
the administration for pharmacokinetic analyses and for rmcroblOlogtcal
analyses. .
Results: In subjects receiving TEL the mean Cmax, AUC and C24 h In
saliva exceeded the values obtained from plasma (1.2 to 5 times). The
quantitative ecological disturbances in the normal microllora during admin-
istration of TEL were moderate and comparable to those of CLA admin-
istration. No overgrowth of yeasts or Clostridium diffUile occurred.
Qualitative alterations in terms of emergence of resistant strains were seen
in both treatment groups. Administration of TEL was associated with
emergence of resistant enterobacteria and bacteroides in faeces, while in
the CLA group emergence of CLA resistant oral streptococci, intestinal
enterococci, enterobacteria and bacteroides were noticed, which partly
persisted two weeks after treatment.
Conclusions: Administration of TEL resulted in high drug levels in saliva,
which indicates a good therapheutic profile for throat infections. TEL seems
to have a more favorable ecological profile compared to eLA, in terms of
resistance development in the normal microflora.
IMoP262!lmpact of antibiotic carryover on the total
antimicrobial effect (AME) of Ievofloxacin against
Staphylococcus aureus in an in vJtro dynamic model
S. Zinnerl , S. Vostrov2, S. Polyakov2, A. Firsov2
1Moutlt Auburn Hospital, Harv«rJ Medical School, Ca",briJA~, MA, U"it,J
States; lCentrejor Science & Technology LekBio Tech, Moscow, Russum
Federation
Objectives: To compare the time-kill curves of S. aureus exposed to
levolloxacin and the total AMEs with and without prevention ofantibiotic
carryover.
Methods: A clinical isolate of S. aureus was exposed to decreasing concen-
trations oflevofloxacin (half-life 6.8 h) with or without IS-min exposure to
antibiotic-removal beads (ARB) - Amberlite XAD-8 (1:1 v/v) at two
simulated AUC/MIC ratios - 116 and 932 (J.tg x h/ml)/(J.tg/ml).
Results: With ARB, CFU numbers of surviving bacteria exposed to the
higher AUCfMIC were slighdy greater during initial and intermediate
killing phases than without ARB, but these differences were not seen during
the regrowth phase. For example, minimal CFUs treated with ARB were
9% higher than without ARB. However. the ditference between the total
antimicrobial effects as expressed by IEs was only 3%. Moreover. there were
no ARB-associated differences in viable counts or IEs at the lower AUC/
MIC ratio.
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Condusion: These results demonstrate that differences between the total
antimicrobial effect with and without ARB over the potentially therapeutic
AUC/MIC range are almost negligible.
IMoP263I Comparative pharmacodynamics of gemifloxacin
(GEM) and levofloxadn (LEV) with Staphylococcus aureus and
Escherichia coil In an in vitro dynamic model
I. lubenko!, S. Vostrov\ A. Firsov\ S. Zinner2
lCentrefor Science & Technology LekBioTech, Moscow, Russian Fedl'ralion;
2Mount Auburn Hospital, Harvard Medical School, Cambridge, MA, United
States
Objectives: To compare the pharmacodynamics ofGEM and lEV in terms
of the AUCfMIC- and dose (D)-response relationships.
Methods: Two clinical isolates of S. aureus and one of E. coli (MICs 0.01,
0.04 and 0.1 J.lg/ml ofGEM and 0.25, 0.6 and 0.2 J'g/ml ofLEV, respectively)
were exposed to monoexponentially decreasing concentrations of GEM
(Tl/2 = 7.4 h) or lEV (Tl/2 = 6.8 h). Eight-fold ranges ofthe AUCfMIC
ratio. 58-466 and 116-932 (J.lg x h/ml)/(/lg/ml), were simulated with GEM
and lEV, respectively. The total AME was expressed by the IE parameter.
Results: linear relationships established between IE and log AUCfMIC of
GEM or lEV were strain-, species- and quinolone-independent (,2 = 0.99 in
each case). The strain-independent patterns of these relationships allowed
extrapolation of the data obtained with specific organisms to hypothetical
strains ofS. aureus and E. coli with MICs = MICSOs (0.04 and 0.03 J.lg/ml of
GEM and 0.7 and 0.03 J.lg/ml oflEV, respectively). Based on the respective
D-response relationships, the equiefficient 24-h Ds of GEM and lEV were
predicted. With E. coli, usual clinical Ds of both GEM (320 mg) and LEV
(500 mg) are able to provide acceptable IEs. With S. aureus, a 320 mg D of
GEM was equiefficient to a much greater D of lEV (3000 mg) that is far in
excess of what may be given clinically.
Condusions: This analysis might be useful to predict in vitro the antimi-
crobial potentials of other newly developed fluoroquinolones.
IMoP264IEffects of grepafloxadn in a murine limb bud
culture
Mehdi Shakibaei, Irmela Baumann-Wilschke!, Marcus RUcker!, Ralf
Stahlmann!
lnstitutjr,r Anatomie; Ilnstitutfr<r Klinische Pharmakologie und Toxikologie,
UKBF, Freie Univl'rSitiit Bl'rlin, Germany
Objectives: To study the affinity of grepaftoxacin to calcium and magne-
sium and to investigate the effects of the quinolone on growth and
differentiation of limb buds from 12-day old mouse embryos in vitro.
Methods: Affinity of grepaftoxacin to divalent cations was determined by
measuring the fluorescence at various concentrations of Mg2 + or Ca2 +.
The drug was added to the culture medium oflimb buds (culture period: 6
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ITu027I Emergence of vancomydn intermediate
Staphylococcus aureus (VISA) in patients with methidllin
resistant S. aureus (MRSA) infection in a Belgian hospital
O. Denis, C. Nonhoff, B. Byl, C. Knoop. M.J. Struelens
Microbiology, Infectious Disease and Pneumology Dpt, Hopital Erasme,
Universite Libre de Bruxelles. Brussels. Belgium
objectives: To detect S. aureus with intermediate susceptibility (VISA) to
vancomycin and to determine its clinical and epidemiological impact in a
860-bed teaching hospital in 1999.
Methods and: results: In 1999, all clinical S. aureus isolates were screened for
decreased susceptibility by vancomycin (6 J.tg/ml) agar screen method
followed by MICs determination (broth microdilution, E-test with 0.5
days) at concentrations between 10 and 100 mgt!. Explants were evaluated
under a dissecting microscope and by electron microscopy.
Results: Grepafloxacin showed a pronounced affinity to calcium as deter-
miend with the fluorescence assay which was higher than the affinities ofsix
other fluoroquinolones tested before (Forster et al. Arch. Toxico!. 72: 411,
1998); affmity to magnesium was similar to that of ciprofloxacin. Grepa-
Aoxacin affecred the growth of the limb buds at concentrations of30 mgfl
and higher; effects were not enhanced when limbs were cultured in a
magnesium-deficient medium. With lower concentrations (10 mgfl) char-
acteristic changes were seen electron microsopically (e.g. detachment ofcell
membrane from matrix, matrixfree periciellular areas, swelling of cell
organelles), higher concentrations caused a completely degraded matrix
and necrotic chondrocytes.
Conclusions: Effects of grepafloxacin in this limb bud assay were more
pronounced than those observed with other quinolones; this might be
related to the rather high affinity of the fluoroquinolone to calcium.
IMoP265] Rlbavlrln treatment of hepatitis C In end stage
renal disease
A. Bruchfeldt, R. Schvarcz2.J. Andersson2,J. -0. Svensson', L. Stahle'
'Renal Medicine; 2Infettious Diseases; JC/inical Pharmacology, Huddinge,
Sweden Hospital; Karolinska Institute
Objective: To investigate the safety ofribavirin treatment in end stage renal
disease (ESRD), since hepatitis C is a prevalent disease in this patient
category. It has been stated repeatedly that ribavirin is contraindicated in
ESRD due to fear of side-effeets. Having recently developed a high-
performance liquid chromatography (HPlC) method to measure ribavirin,
we intended to investigate if close ribavirin drug monitoring and intensive
control ofanemia was safe during interferon-alfa 2b and ribavirin therapy in
ESRD.
Method: Ribavirin was analysed by HPLC after selective solid phase
extraction. Virological, biochemical and clinical status was monitored. 5
patients, 4 on hemodialysis and 1 on peritoneal dialysis, were recruited to the
study.
Results: Ribavirin through levels were initially monitored weekly and
concentrations about 10-12 uM were achieved. The average final dose of
ribavirin was in the range of170-300 mg/day. The peritoneal dialysis patient
did not differ from a pharmacokinetic point of view.
Ribavirin induced anemia was handled by high doses oferythropoeitin. 3
patients completed the intended 28 weeks of treatment (4 weeks of inter-
feron monotherapy followed by 24 weeks of combination therapy). 1
patient had severe interferon related side-effects and therapy was terminated.
1 patient died after 14 weeks due to heart failure associated with severe
cardiac hypertrophy, which was not considered to be treatment related.
Conclusion: The results indicate that ESRD patients can be treated with
ribavirin under strictly conttolled conditions, but it requires dose reduction,
monitoring of ribavirin concentrations as well as high-dose erythropoetin
treatment to avoid severe anemia.
McF inoculum on Mueller Hinton agar and 2 McF inoculum on Brain Heart
Infusion agar) and population analysis. VISA were detected in three patients
colonized with MRSA endemic genotype 1 (sputum from a cystic fibrosis
patient) and genotype 4 (sputum and decubitus ulcer in two ICU patients).
MICs of vancomycin ranged from 8-16 /lg/ml (broth), 4-8 p,g/ml (E-tcst
10':" inoculum) to 1~-32 ~/ml ~-test high inoculum). Resistant subpopu-
lations were seen With 10 -10 frequCDctCS at 8 J.tg/ml. All patients had
received multiple courses of vancomycin for therapy of MRSA lung and
blood infection prior to VISA detection. No secondary spread ofVISA was
found among contact patients or staff. In the CF patient with MRSA/VISA
associated acute exacerbation ofchronic bronchitis, therapy with continuous
vancomycin infusion (20-35 p,g/ml serum) followed with oral minocyclin-
fucidic acid was effective.
Conclusion: In this Belgian hospital, VISA emerged sporadically in patients
under prolonged vancomycin therapy for persistent MRSA infections
